Compare BioNTech SE - ADR (BNTX) vs Morgan Stanley (MS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Morgan Stanley — how do they compare? BioNTech SE - ADR trades at $90.1 (market cap $22.86B), while Morgan Stanley trades at $227.32 (market cap $359.10B). The key difference: Morgan Stanley is far larger — about 15.7× BioNTech SE - ADR's market cap, and Morgan Stanley pays a 1.76% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | MS | |
|---|---|---|
Market Cap | $22.86B | $359.10B |
Sector | Health | Financials |
52-Week High | $119.34 | $228.17 |
52-Week Low | $83.89 | $139.09 |
Enterprise Value | $6.53B | — |
Dividend Yield | — | 1.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Morgan Stanley (MS) trades at $221.09, down 0.54% on the day, with a bullish technical signal from moving averages and strong fundamental performance including three consecutive quarterly earnings beats. Revenue grew to $66.0B in 2025 with net income margin expanding to 25.56%, while analyst consensus remains positive with a $225.80 price target. Recent news highlights the firm's role in leading Anthropic's upcoming IPO and expanding AI integration in wealth management.
The outlook for MS is favorable given earnings momentum and strategic positioning in high-growth areas like AI and IPO advisory, though risks include volatile cash flows and high debt levels. The stock presents a potential 2.1% upside to the consensus target, supported by 53.85% analyst buy ratings, but investors should monitor interest expense and macroeconomic impacts on financial services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →
